DRTS
Brain-cancer data, and the market heard the drum solo
Alpha Tau Medical’s latest update on its U.S. REGAIN study of Alpha DaRT in recurrent glioblastoma was the sort of headline biotech investors love to overreact to — in the fun, potentially-money-making way.
The company said that in the first three patients treated, two showed complete responses, meaning the enhancing tumor lesions disappeared entirely. The third patient had stable disease and a 30% reduction in tumor size. For a cancer with few easy wins, that’s enough to get traders leaning forward in their chairs.
Safety is the other half of the story
The company also said there were no unanticipated serious adverse events as of May 3, 2026. One related grade 3 SAE — a seizure with temporary paralysis — resolved with steroid treatment. That matters because in biotech, a shiny efficacy update is nice, but if the safety profile starts looking like a horror sequel, the stock can give it all back.
Why investors are paying attention
This isn’t a full victory lap; it’s an interim readout from just three patients. But early clinical signals like this can move biotech shares hard because they shape the odds on everything that comes next: more patients, more data, and maybe more credibility for Alpha DaRT in a brutal disease setting.
Separately, Alpha Tau said it completed enrollment in its ReSTART pivotal trial for recurrent cutaneous squamous cell carcinoma, so the company’s pipeline now has more than one shot on goal.
Big picture: when a tiny dataset says “maybe this thing works,” biotech investors hear “keep the popcorn handy.”